Skip to main content
|

Freenome Multiomics Blood Test for Lung Cancer Screening

Short Title: FRNM-007/PROACT


Enrollment Status: Recruiting

NCT #: NCT06122077

Specialty Area: Oncology

Condition Studied: Lung Cancer

Age Groups: Adult; Older Adult

Phase: Not Applicable


Study Information

Summary / Purpose

To find out how well the Freenome blood test detects lung cancer in people at high risk, by comparing it to standard low-dose CT screening.

Study Type: Observational
Accepts Healthy Volunteers: No

Who Can Participate

Eligibility Criteria:
  • Adults 50+ years of age
  • High risk for lung cancer
  • Scheduled to undergo routine low-dose CT (LDCT) screening

What's Involved

Participation in the study will include:
  • Blood sample for the Freenome multiomics test
  • Undergoing standard-of-care low-dose CT (LDCT) lung cancer screening
  • Follow-up for 12 months to monitor for lung cancer diagnosis
  • No treatment is given as part of this study

Principal Investigator

Additional Information

Location: Renown Health, Office of Clinical Research
Address:

1500 E 2nd St. Reno, NV 89502

General Research: 775-982-3646
Oncology Research: 775-982-5050
Email: Renown-CRD@renown.org

Disclaimer: This listing gives you general information about the study and isn't part of the official consent process. If you decide to learn more, the research team will talk with you and check if you meet any additional requirements to join the study.

ER Wait Times

How are wait times calculated?

Our estimated ER wait times reflect the average time from check-in to being seen by a medical professional during triage, where patients are prioritized based on the severity of their condition.

Health & Wellness eNews
Sign Up